Clinical Trial Update: Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy [Phase 3]

View source ↗

Summary

Phase 3 trial results for Viaskin Peanut in children with IgE-mediated peanut allergy have been completed and results posted. The update summarizes the trial's …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2021-10-15